Navigation Links
Neurocrine Biosciences Reports Second Quarter 2011 Results
Date:7/28/2011

General and administrative expenses were $2.8 million for the second quarter of 2011 and $3.1 million during the same period last year. For the six months ended June 30, 2011, general and administrative expenses were $6.0 million, compared to $6.3 million for the first half of 2010. The decrease in general and administrative expenses is primarily due to lower facility related costs.

Other income increased to $0.9 million during the second quarter of 2011 from $0.7 million of income for the second quarter of 2010. Other income decreased from $2.3 million of income during the first half of 2010 to $1.8 million of income for the first half of 2011. The decrease in year-to-date other income resulted from a $0.5 million realized gain on the sale of auction rate securities in the first quarter of 2010.

Pipeline HighlightsElagolix UpdateElagolix Phase III trials for endometriosis are planned to start in the fourth quarter of 2011, with Phase II trials assessing elagolix in uterine fibroids expected to start in the third quarter of 2011.

Additionally, multiple abstracts and datasets from the development program of elagolix for endometriosis will be presented at the 2011 World Congress on Endometriosis to be held September 4-7, 2011 in Montpellier, France.

VMAT2 UpdateThe Company's VMAT2 inhibitor, NBI-98854, successfully completed two Phase I safety studies in healthy male volunteers and a Phase IIa study in tardive dyskinesia patients. Based on these three Canadian studies, the Company filed an Investigational New Drug Application with the FDA Division of Psychiatry.

A second Phase II study is expected to be initiated in the United States in September of this year to further assess NBI-98854 in tardive dyskinesia patients. The design of this Phase II study is a randomized, double-blind, placebo controlled, cross-over trial, using a within-subject comparison for safety and efficacy evaluation. This 32 patient study will as
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
2. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
3. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
5. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
6. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
7. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
8. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... 5 - Evoke Pharma, Inc., a privately-held specialty ... Phase 2b clinical trial to evaluate EVK-001 for the ... is a syndrome characterized by delayed emptying of the ... absence of mechanical obstruction. Diabetes is an important cause ...
... Study Published in the Journal of Rheumatology Examines ... Gout PatientsEAST BRUNSWICK, N.J., May 5 Savient ... today the print publication of the Savient-supported longitudinal ... gout (TFG). The objective of the study was ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
Cached Biology Technology:Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 2Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 4ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... geology as in cancer research, the silver bullet theory always ... wrong. For geologists who study mass extinctions, the silver ... an asteroid is the prime suspect only in the most ... Bottjer. The cataclysm 65 million years ago wiped out the ...
... PORTLAND, Ore. The National Institutes of Health has ... American scientists led by Oregon Health & Science University ... biofuels technology from marine mollusks for development in the ... Philippine archipelago whose waters are inhabited by an estimated ...
... Based on its recent,analysis of the noninvasive ... with the 2008 North American Award for Technology,Innovation ... optics-based,stand-off iris recognition system., The innovative iris ... identify a subject,s iris at a stand-off,distance of ...
Cached Biology News:Extinction by asteroid a rarity 2Discovering drugs, biofuels in tropical seas 2Discovering drugs, biofuels in tropical seas 3Discovering drugs, biofuels in tropical seas 4Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 2Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 3Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 4
Alexa Fluor 647 anti-mouse Qa-2...
... The Luminex 100 Instrument System is ... assays using Upstate's Beadlyte reagents. The ... Dell computer with software version 1.7, ... Delivery System. Upstate offers $2000 in ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: